Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the symbol lookup tool.
Alphabetize the sort order of my symbols
Company Description (as filed with the SEC)
The principal focus of our efforts is to develop and commercialize treatments for hereditary angioedema and to identify other disorders that are mediated by plasma kallikrein. We developed KALBITOR on our own, and since 2010, we have been selling it in the United States for the treatment of acute attacks of HAE. We are also developing DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein, which we believe is a candidate to treat HAE prophylactically. The safety, tolerability, and kallikrein inhibition results of a Phase 1a clinical study in healthy volunteers support advancing the DX-2930 development program into a Phase 1b study in HAE patients in mid-2014. We have also completed development of a biomarker assay that should assist us in detecting the activation of plasma kallikrein in patient blood. ... More ...
|Annual EPS Est:||$-0.26|
|Quarterly EPS Est:||-0.06|